Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers Jakub P. HlávkaTara A. LavellePei-Jung Lin Current Opinion 13 May 2022 Pages: 647 - 652
Considerations Around Coding the Membership Probability Function in a Latent Class Analysis: Renewed Insights Marco BoeriBrett HauberJoseph C. Cappelleri Practical Application 13 June 2022 Pages: 653 - 661
Preference Elicitation Techniques Used in Valuing Children’s Health-Related Quality-of-Life: A Systematic Review Cate BaileyMartin Howellthe Quality of Life in Kids: Key Evidence to Strengthen Decisions in Australia (QUOKKA), Tools for Outcomes Research to Measure, Value Child Health (TORCH) Project Teams Systematic Review Open access 27 May 2022 Pages: 663 - 698
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US Hardik GoswamiAdnan AlsumaliAmy Puenpatom Original Research Article Open access 02 July 2022 Pages: 699 - 714
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China Yichen ZhangYuxuan WeiXiaodong Guan Original Research Article Open access 29 June 2022 Pages: 715 - 724
Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study Shuxia QinXuehong WangXiaomin Wan Original Research Article 15 June 2022 Pages: 725 - 737
Risk-Adjusted Performance Measures: A Comment on Elbasha Pedram SendiMatthias Schwenkglenks Letter to the Editor 17 June 2022 Pages: 739 - 740
Authors’ Reply to Comment on “Risk-Adjusted Performance Measures” Elamin H. Elbasha Letter to the Editor 17 June 2022 Pages: 741 - 742
